BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25901437)

  • 21. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
    Grana G
    J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus in HR-positive advanced breast cancer.
    Tartarone A; Lerose R; Aieta M
    N Engl J Med; 2012 May; 366(18):1739; author reply 1739-40. PubMed ID: 22551140
    [No Abstract]   [Full Text] [Related]  

  • 24. Everolimus in HR-positive advanced breast cancer.
    Massarweh S; Croley J; Weiss H
    N Engl J Med; 2012 May; 366(18):1738-9; author reply 1739-40. PubMed ID: 22551139
    [No Abstract]   [Full Text] [Related]  

  • 25. Hormone therapy in premenopausal women with early-stage breast cancer.
    Rugo HS
    N Engl J Med; 2014 Jul; 371(2):175-6. PubMed ID: 25006724
    [No Abstract]   [Full Text] [Related]  

  • 26. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    González Martín A; de la Cruz S; Márquez R
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
    [No Abstract]   [Full Text] [Related]  

  • 27. Can switching treatments improve breast-cancer outcome?
    Fricker J
    Lancet Oncol; 2006 Jul; 7(7):536. PubMed ID: 16848012
    [No Abstract]   [Full Text] [Related]  

  • 28. [New options in adjuvant endocrine therapy in breast cancer].
    Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
    Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

  • 30. ATAC trial update.
    Del Mastro L; Venturini M
    Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811447
    [No Abstract]   [Full Text] [Related]  

  • 31. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
    Montagna E; Cancello G; Colleoni M
    Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
    Azim HA; Davidson NE; Ruddy KJ
    Am Soc Clin Oncol Educ Book; 2016; 35():23-32. PubMed ID: 27249683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer: some reasons to be hopeful.
    Lancet; 2007 Feb; 369(9561):531. PubMed ID: 17307079
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
    Lindberg H; Nielsen DL; Tuxen M; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3096-100. PubMed ID: 17877958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference.
    Rabaglio M; Aebi S; Castiglione-Gertsch M
    Lancet Oncol; 2007 Oct; 8(10):940-9. PubMed ID: 17913663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant endocrine therapy for premenopausal women: Type and duration.
    Francis PA
    Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Chlebowski RT; Pan K; Col NF
    Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A practical overview of aromatase inhibitors.
    Younus J; Vandenberg TA
    Anticancer Res; 2005; 25(3c):2497-502. PubMed ID: 16080483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine therapy in DCIS: how do we proceed?
    Dixon JM; Jane Macaskill E
    Breast J; 2012; 18(4):295-8. PubMed ID: 22759092
    [No Abstract]   [Full Text] [Related]  

  • 40. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
    Aapro M
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.